|
End-of-day quote
Taiwan S.E.
29/09/2026
|
5-day change | 1st Jan Change | ||
| 47.70 TWD | -0.73% |
|
-0.21% | -19.56% |
| Market Cap | 5.74B 180M 159M 150M 136M 256M 17.27B 258M 1.8B 695M 8.82B 676M 661M 28.38B | P/E 2024 |
52.9x | P/E 2025 | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 6.85B 215M 190M 180M 163M 305M 20.63B 308M 2.15B 830M 10.53B 807M 790M 33.9B | EV / Sales 2024 |
2x | EV / Sales 2025 | 1.7x |
| Free-Float |
78.86% | Yield 2024 |
4.36% | Yield 2025 | 5.06% |
| 1 day | -0.73% | ||
| 1 week | -0.21% | ||
| Current month | -2.15% | ||
| 1 month | -3.34% | ||
| 3 months | -6.10% | ||
| 6 months | -12.80% | ||
| Current year | -19.56% |
| 1 week | 47.45 |  | 49 |
| 1 month | 45 | | 49.6 |
| Current year | 45 | | 62.5 |
| 1 year | 45 | | 68.7 |
| 3 years | 45 | | 121 |
| 5 years | 44.2 | | 121 |
| 10 years | 29.75 | | 121 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CEO | Chief Executive Officer | - | 01/01/1996 |
Yue Chen Lo
DFI | Director of Finance/CFO | - | 14/04/2003 |
Chin Yuan Lin
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CHM | Chairman | - | 01/01/1996 |
Che Jen Chuang
BRD | Director/Board Member | - | 18/06/2012 |
Hung Min Hsieh
BRD | Director/Board Member | - | 28/08/2006 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.73% | -0.21% | -25.82% | -45.61% | 182M | |
| -0.43% | +0.62% | +62.06% | +119.19% | 1,056B | |
| -1.90% | -0.88% | +46.91% | +71.31% | 655B | |
| -1.19% | -0.76% | +17.94% | +76.57% | 471B | |
| -1.72% | -4.06% | +36.39% | +39.47% | 342B | |
| -0.40% | +3.83% | +22.08% | +28.82% | 277B | |
| -0.51% | -1.93% | +12.09% | +11.94% | 257B | |
| +0.13% | +1.88% | +52.56% | +55.52% | 226B | |
| -1.35% | -1.74% | +33.20% | +100.18% | 189B | |
| -0.24% | -2.76% | -28.41% | -60.92% | 170B | |
| Average | -0.84% | +0.85% | +22.90% | +39.65% | 364.31B | |
| Weighted average by Cap. | -0.93% | +1.04% | +38.35% | +69.81% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.73B 148M 131M 124M 112M 211M 14.25B 213M 1.49B 573M 7.27B 557M 545M 23.41B | 4.85B 152M 134M 127M 115M 216M 14.61B 218M 1.52B 588M 7.46B 572M 559M 24B |
| Net income | 157M 4.93M 4.35M 4.12M 3.74M 7.01M 474M 7.08M 49.43M 19.05M 242M 18.53M 18.13M 778M | 441M 13.84M 12.21M 11.56M 10.48M 19.65M 1.33B 19.84M 139M 53.43M 678M 51.97M 50.84M 2.18B |
| Net Debt | 1.2B 37.53M 33.12M 31.33M 28.42M 53.28M 3.6B 53.8M 376M 145M 1.84B 141M 138M 5.92B | 1.12B 35M 30.89M 29.22M 26.5M 49.69M 3.36B 50.18M 351M 135M 1.72B 131M 129M 5.52B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/09/26 | NT$47.70 | -0.73% | 873,174 |
| 24/09/26 | NT$48.05 | -1.23% | 644,992 |
| 23/09/26 | NT$48.65 | +0.93% | 893,123 |
| 22/09/26 | NT$48.20 | +0.84% | 926,534 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4746 Stock
Select your edition
All financial news and data tailored to specific country editions
